Lybrido
Female Sexual Interest/Arousal Disorder (FSIAD) / Hypoactive Sexual Desire Disorder (HSDD)
Phase 2Active
Key Facts
Indication
Female Sexual Interest/Arousal Disorder (FSIAD) / Hypoactive Sexual Desire Disorder (HSDD)
Phase
Phase 2
Status
Active
Company
About Arletta Pharma Solutions
Arletta Pharma Solutions is a clinical-stage biotech addressing the significant unmet medical need in women's sexual health, specifically HSDD and FSIAD. The company's core asset is Lybrido, a combination therapy in Phase II development, which has shown statistically and clinically relevant improvements in clinical studies. Operating from Amsterdam, Arletta positions itself as a specialist in a niche but substantial market where treatment options for women lag decades behind those for men. The company is actively engaged in the scientific community, presenting data at major sexual medicine conferences.
View full company profile